Clinical Trial Results Reported at ASCO on the Use of Celgene`s THALOMID(R) (Thalidomide) for the Treatment of Renal Cell Carcinoma and Glioblastoma
(PR Newswire)...This study evaluated patient response rate and tumor perfusion changes for a median of three cycles (1 cycle = 28 days) of treatment.......About Glioblastoma Multiforme Glioblastoma multiforme is the most aggressive form of the primary brain tumors known collectively as gliomas....- May 16 7:30 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010516/nyw044.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines